Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant Humanized (from mouse) antibody to Human ERBB2. Trastuzumab emtansine (ado-trastuzumab emtansine, trade name trastuzumab emtansine) is an antibody-drug conjugate consisting of the monoclonal antibody trastuzumab (trastuzumab) linked to the cytotoxic agent mertansine (DM1). Trastuzumab alone stops growth of cancer cells by binding to the HER2/neu receptor, whereas mertansine enters cells and destroys them by binding to tubulin. Because the monoclonal antibody targets HER2, and HER2 is only over-expressed in cancer cells, the conjugate delivers the toxin specifically to tumor cells. The conjugate is abbreviated T-DM1.
IgG1 - kappa
Suitable for use in FuncS, IF, Neut, ELISA, FC, IP, ICC and most other immunological methods.
immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (epidermal growth factor receptor 2, HER-2, p185c-erbB2, NEU, EGFR2)], humanizedmonoclonal antibody conjugated to maytansinoid DM1;gamma1 heavy chain (1-449) [humanized VH (Homo sapiens IGHV3-66*01 (81.60%) – (IGHD) – IGHJ6*01 T123>L) [8.8.13] (1-120) – Homo sapiensIGHG1*03 (121-449) CH1 R120>K], (223-214')- disulfide with kappa light chain (1'-214') [humanized V-KAPPA (Homo sapiens IGKV1-39*01 (86.30%) – IGKJ1*01) [6.3.9] (1'-107') – Homo sapiens IGKC*01(108'-214')]; (229-229":232-232")- bisdisulfide dimer;conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM1 via a succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC)linker
>95.0% as determined by analysis by RP-HPLC.
Receptor tyrosine-protein kinase erbB-2, also known as CD340 (cluster of differentiation 340), proto-oncogene Neu, Erbb2 (rodent), or ERBB2 (human) is a protein that in humans is encoded by the ERBB2 gene, which is also frequently called HER2 (from human epidermal growth factor receptor 2) or HER2/neu.
ATP binding; ErbB-3 class receptor binding; Hsp90 protein binding; RNA polymerase I core binding; epidermal growth factor-activated receptor activity; glycoprotein binding; contributes_to growth factor binding; identical protein binding; nucleotide bindin